Cogent Biosciences, Inc.
A clinical-stage biotech company developing precision therapies for genetic diseases.
COGT | US
Overview
Corporate Details
- ISIN(s):
- US19241Q1013 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 275 WYMAN STREET, 2451 WALTHAM
- Website:
- https://www.cogentbio.com/
- Sector:
- Manufacturing
Description
Cogent Biosciences is a clinical-stage biotechnology company focused on developing and commercializing precision therapies for genetically defined diseases. The company designs best-in-class, small molecule therapeutics to target the underlying genetic mutations that cause illnesses such as cancers, rare diseases, and autoimmune conditions. By leveraging validated biology, Cogent aims to address significant unmet medical needs, often by improving upon existing drugs with clear limitations or safety concerns. The company's lead clinical program is bezuclastinib. Cogent's research is dedicated to pioneering novel treatments that can transform the lives of patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cogent Biosciences, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cogent Biosciences, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cogent Biosciences, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
